The use of multiparametric magnetic resonance imaging (mpMRI) and targeted biopsies in patients with elevated prostate-specific antigen (PSA) lead to a significant improvement in the detection of early prostate cancer (PCa) as has been shown in the PROMIS trial [1]. This evidence concerns the gene KLK3 and Familial prostate cancer.